In a decision issued by the Federal Circuit on October 24, 2018, the court affirmed a finding by the Patent Trial and Appeal Board (PTAB) that a multiple sclerosis (MS) treatment claimed in an application owned by FWP IP APS
Patent 213
New thinking on written description, enablement and patent eligibility issues
Patent 213 is a blog published by Bradley Arant Boult Cummings LLP that focuses on issues related to patent law and intellectual property. The blog covers topics such as patent eligibility under Section 101, patent prosecution strategies, litigation outcomes, and recent court decisions affecting patent rights. It discusses developments in various technology sectors including software, gaming, biotechnology, and medical diagnostics. The blog also highlights the work and achievements of Bradley's patent attorneys and provides insights into managing patent portfolios and intellectual property strategies. It serves as a resource for understanding complex patent law issues and recent trends in patent enforcement and defense.
Latest from Patent 213 - Page 2
Business Method and Software Patent Eligibility: Australian and U.S. Standards
This is the first of a two-part series comparing Australian and U.S. law and will focus on software and computer-related inventions.
While U.S. patent owners, applicants, and the bar have been seeking clarification from the courts and U.S. Patent &…
